References
- Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. (London, England). 2018; 391: 2547–2559.
- Fosby B, Melum E, Bjøro K, et al. Liver transplantation in the Nordic countries - an intention to treat and post-transplant analysis from the nordic liver transplant registry 1982-2013. Scand J Gastroenterol. 2015;50:797–808.
- Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161–1170.
- Weersma RK, Lindor KD. Shifting paradigms: what is the true prevalence and clinical course of primary sclerosing cholangitis? Gastroenterology. United States. 2016: 590–593
- Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–2055.
- Bakhshi Z, Hilscher MB, Gores GJ, et al. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. J Gastroenterol. 2020;55:523–532.
- Lindkvist B, Benito de Valle M, Gullberg B, et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in sweden. Hepatology. 2010;52:571–577.
- Azzam N, AlRuthia Y, Alharbi O, et al. Factors associated with major radiological progression of primary sclerosing cholangitis in patients with inflammatory bowel disease. Hepatol Int. Internet]. 2020;14:1114–1124. Available from. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098111636&doi=10.1007%2Fs12072-020-10110-5&partnerID=40&md5=5314d343d9963807362117afdbd28daf
- Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. Internet]. 2020;5:17–30. Available from.;: .:https://www.sciencedirect.com/science/article/pii/S2468125319303334
- Olfatifar M, Zali MR, Pourhoseingholi MA, et al. The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: a modeling study. BMC Gastroenterol. 2021;21:204.
- Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2011;18:154–161.
- Eaton JE, McCauley BM, Atkinson EJ, et al. Variations in primary sclerosing cholangitis across the age spectrum. J Gastroenterol Hepatol. 2017;32:1763–1768.
- Ponsioen CY. Diagnosis, differential diagnosis, and epidemiology of primary sclerosing cholangitis. Dig Dis. 2015;33(2):134–139.
- Tanaka A, Takamori Y, Toda G, et al. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int Off J Int Assoc Study Liver. 2008;28:983–989.
- Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102:344–350.
- Fraga M, Fournier N, Safroneeva E, et al. Primary sclerosing cholangitis in the swiss inflammatory bowel disease cohort study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol. 2017;29:91–97.
- Lunder AK, Hov JR, Borthne A, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology. 2016;151:660–669.e4.
- Hadizadeh M, Abedi SH, Malekpour H, et al. Prevalence of inflammatory bowel disease among patients with primary sclerosing cholangitis in Iran. Arab J Gastroenterol. Internet]. 2016;17:17–19. Available from.;: .:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963761923&doi=10.1016%2Fj.ajg.2015.09.004&partnerID=40&md5=42c531a606636b9b3eeae13f8469f952
- Barner-Rasmussen N, Pukkala E, Hadkhale K, et al. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United Eur Gastroenterol J. 2021;9:1128–1135.
- Liang H, Manne S, Shick J, et al. Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Med (United States). Internet]. 2017;96. Available from.; . https://www.scopus.com/inward/record.uri?eid=2-s2.0-85022095826&doi=10.1097%2FMD.0000000000007116&partnerID=40&md5=c211bdd5782a6717445a32367cc26463
- Escorsell A, Parés A, Rodés J, et al. Epidemiology of primary sclerosing cholangitis in Spain. J Hepatol. Internet]. 1994;21:787–791. Available from.;: .:https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027971759&doi=10.1016%2FS0168-8278%2894%2980240-8&partnerID=40&md5=cd1ff0ce632888e572afdca25e8d4aa0
- Yanai H, Matalon S, Rosenblatt A, et al. Prognosis of primary sclerosing cholangitis in Israel is independent of coexisting inflammatory bowel disease. J Crohn’s Colitis. Internet]. 2015;9:177–184. Available from.;: .:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947735506&doi=10.1093%2Fecco-jcc%2Fjju013&partnerID=40&md5=328a6cf5b44bf4f2a48d815b4cdb031d
- Rönnblom A, Holmström T, Tanghöj H, et al. Appearance of hepatobiliary diseases in a population-based cohort with inflammatory bowel diseases (Inflammatory Bowel Disease Cohort of the Uppsala Region). J Gastroenterol Hepatol. Internet]. 2015;30:1288–1292. Available from.;: .:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937440962&doi=10.1111%2Fjgh.12947&partnerID=40&md5=170650fba0e1c3245698158245c566c7
- Park S-K, Wong Z, Park SH, et al. Extraintestinal manifestation of inflammatory bowel disease in Asian patients: a multinational study. Dig Liver Dis. Internet]. 2021;53:196–201. Available from.;: .:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088986744&doi=10.1016%2Fj.dld.2020.06.046&partnerID=40&md5=8d9e601753c105f9fcc2e9dd2e0d9f85
- Algaba A, Guerra I, Ricart E, et al. Extraintestinal manifestations in patients with inflammatory bowel disease: study based on the eneida registry. Dig Dis Sci. Internet]. 2021;66:2014–2023. Available from.;: .:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087878212&doi=10.1007%2Fs10620-020-06424-x&partnerID=40&md5=bc41688739d290e084a87457bf036e29
- Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol. 2017;14:279–295.
- Azizi G, Khadem Azarian S, Nazeri S, et al. Monogenic auto-infiammatory syndromes: a review of the literature. Iran J Allergy Asthma Immunol. 2016;15:430–444.
- Vierling JM. Immunology of primary sclerosing cholangitis. 2020. p. 111–131. Available from: https://app.dimensions.ai/details/publication/pub.1031583678.
- de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49:256–261.
- Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298–1323.
- Næss S, Lie BA, Melum E, et al. Refinement of the MHC risk map in a scandinavian primary sclerosing cholangitis population. PLoS One. 2014;9:e114486.
- Marsh SGE, Parham P, Barber LD. Part 11 - HLA-DR. Marsh SGE, Parham P, Barber LDB-T-THLAF, editors. Factsbook [Internet]. London: Academic Press; 2000. p. 329–390. Available from http://www.sciencedirect.com/science/article/pii/B9780125450256501544
- Marsh SGE, Parham P, Barber LD. Part 2 - HLA-B. In: Marsh SGE, Parham P, Barber LDB-T-THLAF, editors. Factsbook [Internet]. London: Academic Press; 2000. p. 151–241. Available from http://www.sciencedirect.com/science/article/pii/B9780125450256501453
- Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102–1111.
- Bowlus CL, Li C-S, Karlsen TH, et al. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2010;16:1324–1330.
- Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979–986.
- Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43:17–19.
- Srivastava B, Mells GF, Cordell HJ, et al. Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis. Scand J Gastroenterol. 2012;47:820–826.
- Ellinghaus D, Folseraas T, Holm K, et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology. 2013;58:1074–1083.
- Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45:670–675.
- Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48:510–518.
- Karlsen TH, Hampe J, Wiencke K, et al. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol. 2007;102:115–121.
- Ji S-G, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49:269–273.
- Chung BK, Hirschfield GM. Immunogenetics in primary sclerosing cholangitis. Curr Opin Gastroenterol. 2017;33:93–98.
- Farh KK-H, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518:337–343.
- Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–2075.
- Sharma M, Krüger R, Gasser T. From genome-wide association studies to next-generation sequencing: lessons from the past and planning for the future. JAMA Neurol. 2014; 71: 5–6. Internet].;:. Available from.
- Henriksen EKK, Melum E, Karlsen TH. Update on primary sclerosing cholangitis genetics. Curr Opin Gastroenterol. 2014;30:310–319.
- Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–615.
- Loftus EVJ, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–96.
- Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33:854–862.
- O’Toole A, Alakkari A, Keegan D, et al. Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10:439–441.
- de Vries AB, Janse M, Blokzijl H, et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21:1956–1971.
- Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC Phenotypes of PSC-IBD. Curr Gastroenterol Rep. 2018;20:16.
- Aranake-Chrisinger J, Dassopoulos T, Yan Y, et al. Primary sclerosing cholangitis associated colitis: characterization of clinical, histologic features, and their associations with liver transplantation. World J Gastroenterol. 2020;26:4126–4139.
- Jørgensen KK, Grzyb K, Lundin KEA, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis. 2012;18:536–545.
- Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152:1975–1984.e8.
- Fevery J, Van Steenbergen W, Van Pelt J, et al. Patients with large-duct primary sclerosing cholangitis and Crohn’s disease have a better outcome than those with ulcerative colitis, or without IBD. Aliment Pharmacol Ther. 2016;43:612–620.
- Cordes F, Laumeyer T, Gerß J, et al. Distinct disease phenotype of ulcerative colitis in patients with coincident primary sclerosing cholangitis: evidence from a large retrospective study with matched cohorts. Dis Colon Rectum. 2019;62:1494–1504.
- Schaeffer DF, Win LL, Hafezi-Bakhtiari S, et al. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci. 2013;58:2608–2614.
- Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3497–3503.
- Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011;60:1224–1228.
- Navaneethan U, Rai T, Venkatesh PG, et al. Primary sclerosing cholangitis and the risk of colon neoplasia in patients with Crohn’s colitis. Gastroenterol Rep. 2016;4:226–231.
- Lindström L, Jørgensen KK, Boberg KM, et al. Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study. Scand J Gastroenterol. 2018;53:297–304.
- Ravikumar R, Tsochatzis E, Jose S, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63:1139–1146.
- Franceschet I, Cazzagon N, Del Ross T, et al. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. Eur J Gastroenterol Hepatol. 2016;28:508–513.
- Mertz A, Nguyen NA, Katsanos KH, et al. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol. 2019;32:124–133.
- Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48:939–944.
- Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol. 2019;25:659–671.
- Rizvi S, Eaton JE, Gores GJ. Primary sclerosing cholangitis as a premalignant biliary tract disease: surveillance and management. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13:2152–2165.
- Tanaka A, Takikawa H. Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun. 2013;46:35–40.
- Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526.
- Gulamhusein AF, Eaton JE, Tabibian JH, et al. Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol. 2016;111:705–711.
- Björnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–980.
- Trivedi PJ, Crothers H, Mytton J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology. 2020;159:915–928.
- Bowlus CL, Lim JK, Lindor KD. AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: expert review. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17:2416–2422.
- Zenouzi R, Weismüller TJ, Hübener P, et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12:1733–1738.
- Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. 2017. DOI:https://doi.org/10.1016/j.jhep.2017.07.033.
- Francescone R, Hou V, Grivennikov SIC. IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015;21:409–418.
- Guerra I, Bujanda L, Castro J, et al. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicentre retrospective cohort study. J Crohns Colitis. 2019;13:1492–1500.
- Claessen MMH, Vleggaar FP, Tytgat KMAJ, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–164.
- Zheng -H-H, Jiang X-L. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol. 2016;28:383–390.
- Braden B, Halliday J, Aryasingha S, et al. Risk for colorectal neoplasia in patients with colonic Crohn’s disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10:303–308.
- Shah SC, Ten Hove JR, Castaneda D, et al. High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16:1106–1113.e3.
- Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46–55.
- Thackeray EW, Charatcharoenwitthaya P, Elfaki D, et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:52–56.
- Rao BB, Lashner B, Kowdley KV. Reviewing the risk of colorectal cancer in inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2018;24:269–276.
- Ananthakrishnan AN, Cagan A, Gainer VS, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis. 2014;8:956–963.
- Quraishi MN, Acharjee A, Beggs AD, et al. A pilot integrative analysis of colonic gene expression, gut microbiota, and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways. J Crohn’s Colitis. 2020;14:935–947.
- Beggs AD, James J, Caldwell G, et al. Discovery and validation of methylation biomarkers for ulcerative colitis associated neoplasia. Inflamm Bowel Dis. 2018;24:1503–1509.
- Hu W, Yang Y, Li X, et al. Multi-omics approach reveals distinct differences in left- and right-sided colon cancer. Mol Cancer Res. 2018;16:476–485.
- Little R, Wine E, Kamath BM, et al. Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroenterol. 2020;26:2768–2780.
- Sung CM, Lin Y-F, Chen K-F, et al. Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome. Cell Mol Gastroenterol Hepatol. 2019;8:301–318.e2.
- Rossen NG, Fuentes S, Boonstra K, et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis. 2015;9:342–348.
- Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65:1681–1689.
- Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol. 2017;23:4548–4558.
- Rühlemann M, Liwinski T, Heinsen F-A, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019;50:580–589.
- Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635–700.
- Lemoinne S, Kemgang A, Ben Belkacem K, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. Internet]. 2020;69:92–102. Available from.;: .:http://gut.bmj.com/content/69/1/92.abstract
- Dean G, Hanauer S, Levitsky J. The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications. Hepatology. 2020; 72: 1127–1138.